Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Summary

LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.

Timeline

Start

2023-10-27

Primary completion

2029-03

Completion

2029-10

Publications

• Capdevila J, Pubul V, Anido U, Walter T, Molina-Cerrillo J, Alonso-Gordoa T, Garcia-Carbonero R, San-Roman-Gil M, Llana B, Jimenez-Fonseca P, Benavent Vinuales M, Ansquer C, Baudin E, Lepage C, Del Olmo-Garcia M, Ruffinelli JC, Beron A, Haissaguerre M, Deshayes E, Taieb D, Baldari S, Sansovini M, Cingarlini S, Filice A, Panzuto F, Alvarez-Alvarez R, Lousberg L, Aboubakar Nana F, Hernando J, Garcia-Alvarez A, Garcia-Burillo A, Villacampa G, Vandamme T, Fazio N, Durand A. A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). BMC Cancer. 2025 Apr 4;25(1):613. doi: 10.1186/s12885-025-13941-3.

Drugs

Indications